London Stock Exchange welcomes BiVictriX Therapeutics plc
London Stock Exchange today welcomes BiVictriX Therapeutics plc (“BiVictriX”), a rapidly emerging drug discovery and development company that begins trading on AIM under the ticker symbol BVX, following a successful initial public offering.
BiVictriX has successfully raised gross proceeds of £7.5 million by way of a placing and subscription at a market capitalisation of approximately £13.2 million. The funds will enable BiVictriX to accelerate its growth strategy and expedite the development and delivery of its next-generation, highly selective cancer therapeutics.
Founded by Tiffany Thorn in 2017, BiVictriX is applying a novel approach, derived from frontline clinical experience from within the NHS, to create safer, more effective cancer therapeutics. BiVictriX has developed a proprietary platform and the resulting Bi-Cygni® therapeutics are uniquely selective for the specific cancers, potentially enabling higher dosing and more aggressive tumour eradication, while reducing life-threatening treatment-related side effects.
Tiffany Thorn, Founder and CEO of BiVictriX, said: “Today’s listing on London’s AIM is a major milestone for BiVictriX. Our vision is to revolutionise cancer therapy for the most difficult to treat cancers, making curative treatments available to all. The funds raised will help us to accelerate our growth strategy and expedite the development and delivery of our pioneering, highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers. Supporting patients who are currently in urgent need of more effective medicines.
“I would like to take this opportunity to offer our sincere gratitude and thanks to all of our staff, advisers and shareholders who have been instrumental in getting us to where we are today. I would also like to take this opportunity to welcome new shareholders to the register and thank them for their support in enabling us to continue to carry out this critical work. I look forward to life as a public company and progressing our development programmes to the next stage with the support of our shareholders.”
Advisers to the IPO include:
- SP Angel Corporate Finance LLP – Nominated Adviser and Broker
- Acceleris Capital Limited – Financial Adviser
- Slater Heelis Limited – Solicitors to BiVictriX
- Gowlings WLG (UK) LLP – Solicitors to SP Angel
- Crowe U.K. LLP – Reporting Accountant and Auditor
- Consilium Strategic Communications – Financial Public Relations Adviser